Physicians can now order the Shield blood test through Quest's network of nearly 650,000 clinician and hospital accounts, patient service centers, and in-office phlebotomists.
HerAnova Lifesciences has launched HerResolve, the first blood-based test for endometriosis detection, at IVF centers nationwide. Validation studies show diagnostic accuracy comparable to surgical standards, according to the company.
The Galleri blood test demonstrated a four-fold increase in cancer detection rates and substantial reduction in stage IV cancer diagnoses in 142,000 participants.
The integrated testing approach combines genomic profiling with immunohistochemistry to support faster treatment decisions for advanced-stage cancer patients.
The CDC has named Cepheid one of four national collaborators to accelerate rapid diagnostic assay development for public health emergencies under a new federal initiative and IDIQ contract.
PD-L1 testing is now cleared to help identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who may be eligible for anti–PD-1 therapy.
Castle Biosciences' AdvanceAD-Tx test identifies patients more likely to respond to JAK inhibitor therapy versus Th2-targeted treatments.
The test measures two sugar alcohols to detect SORD-related neuropathy, which standard genetic tests sometimes miss.
The test uses five biomarkers and proprietary technology to detect amyloid brain plaques in patients with cognitive symptoms.
Babson Diagnostics’ BetterWay GLP-1 blood testing panel is now available at more than 25 Austin and Temple, Texas, retail locations, including Sam’s Club and Peoples Rx pharmacies. The panel features 29 tests to support GLP-1 therapy.
The agreement aims to improve early detection and management of chronic kidney disease in underserved populations through integrated diagnostics and digital health solutions.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The eight-minute test also shortened hospital stays by nearly two days at Froedtert Hospital, reinforcing previous multi-site evidence.